Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–10. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer version 7.2019 [ accessed 2019 Jan 01]. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152. doi:10.1016/S1470-2045(17)30074-8.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104(20):1534–1541. doi:10.1093/jnci/djs353.
   PubMedGoogle Scholar
• Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, et al. Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. J Thorac Oncol. 2019;14(3):468–474. doi:10.1016/j.jtho.2018.10.167.
   PubMed Web of Science ®Google Scholar
• Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38–47. doi:10.1016/j.ejca.2017.10.017.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res. 2017;23(16):4671–4679. doi:10.1158/1078-0432.CCR-17-0114.
   PubMed Web of Science ®Google Scholar
• Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, Nachiappan AC, Simone CB, Langer CJ. Radiologic pseudoprogression during Anti-PD-1 therapy for advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(7):978–986. doi:10.1016/j.jtho.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, et al. Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012. doi:10.1200/JCO.2014.58.3708.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35(1):1–39. doi:10.1038/bjc.1977.1.
   PubMed Web of Science ®Google Scholar
• Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York (NY): Springer Science & Business Media; 2013.
   Google Scholar
• Therneau TM, Li H. Computing the cox model for case cohort designs. Lifetime Data Anal. 1999;5(2):99–112. doi:10.1023/A:1009691327335.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543–1552. doi:10.1001/jamaoncol.2018.3676.
   PubMed Web of Science ®Google Scholar
• Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, et al. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. Int J Cancer. 2019;144(5):1170–1179. doi:10.1002/ijc.31923.
   PubMed Web of Science ®Google Scholar
• Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM. Tumor response dynamics of advanced non-small cell lung cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin Cancer Res. 2017;23(19):5737–5744. doi:10.1158/1078-0432.CCR-17-1434.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol. 2017;44(1):3–7. doi:10.1053/j.seminoncol.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Kim HK, Baek SW, Jeong Y, Yang Y, Kwon J, Han HS, An J-Y, Woo CG, Lee O-J, Lee TG, et al. Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report. Mol Clin Oncol. 2019;11(2):132–134. doi:10.3892/mco.2019.1871.
   PubMed Web of Science ®Google Scholar
• Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117(4):451–460. doi:10.1038/bjc.2017.220.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–1517. doi:10.1200/JCO.2015.64.0391.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi:10.1158/1078-0432.CCR-09-1624.
   PubMed Web of Science ®Google Scholar
• George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016;2(9):1179–1186. doi:10.1001/jamaoncol.2016.0775.
   PubMed Web of Science ®Google Scholar
• Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkMate 025. Eur Urol. 2017;72(3):368–376. doi:10.1016/j.eururo.2017.03.037.
   PubMed Web of Science ®Google Scholar
• Long GV, Weber JS, Larkin J, Atkinson V, Grob -J-J, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol. 2017;3(11):1511–1519. doi:10.1001/jamaoncol.2017.1588.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS, Awad MM. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016;4(1):84. doi:10.1186/s40425-016-0193-2.
   PubMed Web of Science ®Google Scholar
• Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2(1):17. doi:10.1186/2051-1426-2-17.
   PubMedGoogle Scholar
• Marciscano AE, Thorek DLJ. Role of noninvasive molecular imaging in determining response. Adv Radiat Oncol. 2018;3(4):534–547. doi:10.1016/j.adro.2018.07.006.
   PubMedGoogle Scholar
• Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS. Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med. 2017;58(4):538–546. doi:10.2967/jnumed.116.177659.
   PubMed Web of Science ®Google Scholar